Andrew D Kelly
Overview
Explore the profile of Andrew D Kelly including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
403
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lietz C, Newman E, Kelly A, Xiang D, Zhang Z, Ramavenkat N, et al.
medRxiv
. 2024 Jul;
PMID: 38946948
Osteosarcoma is a rare primary bone tumor for which no significant therapeutic advancement has been made since the late 1980s despite ongoing efforts. Overall, the five-year survival rate remains about...
2.
Lietz C, Newman E, Kelly A, Xiang D, Zhang Z, Luscko C, et al.
Commun Biol
. 2022 Mar;
5(1):213.
PMID: 35260776
Aberrant methylation of genomic DNA has been reported in many cancers. Specific DNA methylation patterns have been shown to provide clinically useful prognostic information and define molecular disease subtypes with...
3.
Kelly A, Murugesan K, Kuang Z, Montesion M, Ross J, Albacker L, et al.
J Immunother Cancer
. 2021 Nov;
9(11).
PMID: 34815356
Background: Immune checkpoint inhibitors (ICIs) benefit patients with multiple cancer types, however, additional predictive biomarkers of response are needed. (programmed cell death ligand-1, PD-L1) gene rearrangements are positively associated with...
4.
Kelly A, Wiklund T, Kononen J, Creeden J
JCO Precis Oncol
. 2021 Aug;
5.
PMID: 34423228
No abstract available.
5.
Chung W, Kelly A, Kropf P, Fung H, Jelinek J, Su X, et al.
Clin Epigenetics
. 2019 Jul;
11(1):106.
PMID: 31331399
Background: Guadecitabine is a novel DNA methyltransferase (DNMT) inhibitor with improved pharmacokinetics and clinical activity in a subset of patients with relapsed/refractory acute myeloid leukemia (r/r AML), but identification of...
6.
Good C, Panjarian S, Kelly A, Madzo J, Patel B, Jelinek J, et al.
Cancer Res
. 2018 Jun;
78(15):4126-4137.
PMID: 29891505
Both gains and losses of DNA methylation are common in cancer, but the factors controlling this balance of methylation remain unclear. Triple-negative breast cancer (TNBC), a subtype that does not...
7.
Kelly A, Madzo J, Madireddi P, Kropf P, Good C, Jelinek J, et al.
Leukemia
. 2018 Mar;
32(10):2178-2188.
PMID: 29556023
Acute myeloid leukemia (AML) often harbors mutations in epigenetic regulators, and also has frequent DNA hypermethylation, including the presence of CpG island methylator phenotypes (CIMPs). Although global hypomethylation is well...
8.
Werner R, Kelly A, Issa J
Cancer J
. 2017 Sep;
23(5):262-269.
PMID: 28926426
Epigenetic alterations such as DNA methylation defects and aberrant covalent histone modifications occur within all cancers and are selected for throughout the natural history of tumor formation, with changes being...
9.
Hill K, Kelly A, Kuijjer M, Barry W, Rattani A, Garbutt C, et al.
J Hematol Oncol
. 2017 May;
10(1):107.
PMID: 28506242
Background: A microRNA (miRNA) collection on the imprinted 14q32 MEG3 region has been associated with outcome in osteosarcoma. We assessed the clinical utility of this miRNA set and their association...
10.
Kelly A, Issa J
Curr Opin Genet Dev
. 2017 Apr;
42:68-77.
PMID: 28412585
Epigenetics refers to heritable molecular determinants of phenotype independent of DNA sequence. Epigenetic features include DNA methylation, histone modifications, non-coding RNAs, and chromatin structure. The epigenetic status of cells plays...